Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Head & Neck 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Myelodysplastic Syndromes 30Leukemia, Myeloid, Acute 22Myeloproliferative Disorders 15Leukemia, Myelomonocytic, Chronic 13Myelodysplastic-Myeloproliferative Diseases 9Primary Myelofibrosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 6Polycythemia Vera 5Neuroblastoma 5Leukemia 5Histiocytosis, Langerhans-Cell 5Wilms Tumor 4Thrombocythemia, Essential 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4Multiple Myeloma 4Medulloblastoma 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Hepatoblastoma 4Glioma 4Ependymoma 4Central Nervous System Neoplasms 4Anemia 4Thrombocytosis 3Sarcoma 3Rhabdomyosarcoma 3Osteosarcoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Biphenotypic, Acute 3

Interventions

fludarabine phosphate 34Cyclophosphamide 31Peripheral Blood Stem Cell Transplantation 27Mycophenolic Acid 25Cyclosporine 23Antilymphocyte Serum 23Busulfan 20Tacrolimus 17Radiotherapy 17Filgrastim 17Whole-Body Irradiation 15Methotrexate 15Methylprednisolone 14Melphalan 13Cord Blood Stem Cell Transplantation 12venetoclax 9Cytarabine 8Azacitidine 8fludarabine 5Etoposide 5sargramostim 4Therapeutics 4Sirolimus 4Decitabine 4Clofarabine 4Alemtuzumab 4thymoglobulin 3nilotinib 3merphos 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Biopsy × Myeloid × Clear all
NCT05564650 2026-05-19

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Thomas Jefferson University

Phase 1 Completed
6 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡